Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, May 31 '25)


 

    Arch Virol

  1. LIU X
    ACE2, a therapeutic target of COVID-19, needs to be treated with caution.
    Arch Virol. 2025;170:143.
    PubMed         Abstract available


    BMJ

  2. IBRAHIM S, Siemieniuk RAC, Oliveros MJ, Islam N, et al
    Drug treatments for mild or moderate covid-19: systematic review and network meta-analysis.
    BMJ. 2025;389:e081165.
    PubMed         Abstract available


    J Immunol

  3. DING C, Chen Q, Shi Y, Liu J, et al
    Impact of CD4+ T cell and TCR repertoires on SARS-CoV-2-Specific antibody responses in PLWH following COVID-19 vaccination.
    J Immunol. 2025 Apr 15:vkae040. doi: 10.1093.
    PubMed         Abstract available


    J Infect

  4. PETER RS, Sedelmaier L, Nieters A, Brockmann SO, et al
    Symptom burden and post-COVID-19 syndrome 24 months following SARS-CoV-2 infection: Longitudinal population-based study.
    J Infect. 2025;90:106500.
    PubMed         Abstract available

  5. HOOG M, Westrhenen ESH, Winkel AM, Jong MD, et al
    Impact of co-infection with SARS-CoV-2 and other respiratory viruses on illness: Pooled analyses of 11 COVID-19 cohorts.
    J Infect. 2025 May 9:106501. doi: 10.1016/j.jinf.2025.106501.
    PubMed         Abstract available

  6. RIEDMANN U, Chalupka A, Richter L, Werber D, et al
    Underlying health biases in previously-infected SARS-CoV-2 vaccination recipients: a cohort study.
    J Infect. 2025 Apr 30:106497. doi: 10.1016/j.jinf.2025.106497.
    PubMed         Abstract available

  7. OVERTON CE, Fyles M, Mellor J, Paton RS, et al
    SARS-CoV-2 test sensitivity and duration of positivity in the UK during the 2023/2024 Winter: A prospective cohort study based on self-reported data.
    J Infect. 2025;90:106485.
    PubMed         Abstract available

  8. CHEN R, Hao Z, Ye J, Zhao X, et al
    Decoding Post-Mortem Infection Dynamics of SARS-CoV-2, IAV and RSV: New Insights for Public Health and Emerging Infectious Diseases Management.
    J Infect. 2025 Apr 21:106489. doi: 10.1016/j.jinf.2025.106489.
    PubMed         Abstract available


    J Virol

  9. ZHANG Q, Zhang L, Li J, Zhang W, et al
    hnRNPM regulates influenza A virus replication through distinct mechanisms in human and avian cells: implications for cross-species transmission.
    J Virol. 2025 May 28:e0006725. doi: 10.1128/jvi.00067.
    PubMed         Abstract available


    JAMA

  10. MOIN EE, Seewald NJ, Halpern SD
    Use of Life Support and Outcomes Among Patients Admitted to Intensive Care Units.
    JAMA. 2025 Apr 14:e252163. doi: 10.1001/jama.2025.2163.
    PubMed         Abstract available


    PLoS Comput Biol

  11. ZHANG R, Tai J, Yao Q, Yang W, et al
    Behavior-driven forecasts of neighborhood-level COVID-19 spread in New York City.
    PLoS Comput Biol. 2025;21:e1012979.
    PubMed         Abstract available

  12. MEDINA CM, Palacios JA, Minin VM
    Accounting for reporting delays in real-time phylodynamic analyses with preferential sampling.
    PLoS Comput Biol. 2025;21:e1012970.
    PubMed         Abstract available


    PLoS One

  13. REHMAN N, Mbuagbaw L, Mertz D, Muraca GM, et al
    Association between virtual visits and health outcomes of people living with HIV: A cross-sectional study.
    PLoS One. 2025;20:e0315880.
    PubMed         Abstract available

  14. DHAR B, Sajid M
    On improving public health after COVID-19 epidemic: A fractal-fractional mathematical solutions with short memory effect and efficient optimal strategies.
    PLoS One. 2025;20:e0321195.
    PubMed         Abstract available

  15. KUANG D, Gao X, Du N, Huang J, et al
    Wastewater surveillance as a predictive tool for COVID-19: A case study in Chengdu.
    PLoS One. 2025;20:e0324521.
    PubMed         Abstract available

  16. HONDA R, Abe T, Baba T, Araki Y, et al
    Dissemination of local sub-variants of SARS-CoV-2 detected by detailed mutation analysis in wastewater-based epidemiology.
    PLoS One. 2025;20:e0317076.
    PubMed         Abstract available

  17. HAN Z, Chen M, Wang Y
    The impact of COVID-19 stress on nurses' organizational deviance: A moderated mediation model.
    PLoS One. 2025;20:e0324992.
    PubMed         Abstract available

  18. CAZER CL, Lawless JW, Mehta P, Wagner B, et al
    Prevalence of SARS-CoV-2 infection and immunity in a New York county in 2022 reveals frequent asymptomatic or undiagnosed infections.
    PLoS One. 2025;20:e0323659.
    PubMed         Abstract available

  19. AXEN I, Weiss N, Skillgate E
    Manual therapists in Sweden during the COVID-19 pandemic -they remained in business, but how was their work environment and practice impacted?
    PLoS One. 2025;20:e0324245.
    PubMed         Abstract available

  20. HEYDARI P, Meyer MN, Chabris CF
    Medical rationing choices of laypeople and clinicians are often illogical and inconsistent with their own stated preferences.
    PLoS One. 2025;20:e0322242.
    PubMed         Abstract available

  21. ALTARE C, Kim K, Spiegel PB
    "Everything had stopped, no meeting, no gathering": Social interactions during the COVID-19 pandemic in the Central African Republic, the Democratic Republic of Congo, and Bangladesh.
    PLoS One. 2025;20:e0323108.
    PubMed         Abstract available

  22. KENGNE KAMGA LS, Voordouw ACG, De Vries MC, Kemper S, et al
    The citizen's perception of a shared responsibility during the COVID-19 management: Insights from a focus group study across four European countries.
    PLoS One. 2025;20:e0322019.
    PubMed         Abstract available

  23. RUSSO FF
    Testing policies during an epidemic: An economic analysis.
    PLoS One. 2025;20:e0322292.
    PubMed         Abstract available

  24. POORBAUGH J, Sims JT, Zhang L, Chang CY, et al
    Serum IL-6 and PTX3 predict severe outcome from COVID-19 in ambulatory subjects: Impact for future therapeutic decisions.
    PLoS One. 2025;20:e0324242.
    PubMed         Abstract available

  25. MANUEL DG, Bennett C, Brown E, Buckeridge DL, et al
    Developing an evaluation framework for public health environmental surveillance: Protocol for an international, multidisciplinary Delphi consensus study.
    PLoS One. 2025;20:e0310342.
    PubMed         Abstract available

  26. SHIMIZU HE, Gomes AMT, Apostolidis T
    The social representations of Covid-19 among primary health care' users in the Federal district, Brazil: A psychosocial approach.
    PLoS One. 2025;20:e0323568.
    PubMed         Abstract available

  27. MA X, Huang T, Song Y, Pan H, et al
    Bioinformatics and system biology approach to discover the common pathogenetic processes between COVID-19 and chronic hepatitis B.
    PLoS One. 2025;20:e0323708.
    PubMed         Abstract available

  28. NYONGESA V, Kathono J, Mwavua S, Nyamai D, et al
    "If I tell you my problems, how will you perceive me?": A qualitative study of mental health knowledge, barriers, and opportunities for care among Kenyan adolescents during COVID-19.
    PLoS One. 2025;20:e0323907.
    PubMed         Abstract available

  29. SONG MC, Ha J, Park S, Kang H, et al
    Mortality in severe serious adverse events following heterologous and homologous prime-boost vaccination strategies for SARS-CoV-2: A retrospective cohort study.
    PLoS One. 2025;20:e0323736.
    PubMed         Abstract available

  30. NATALIA YA, Molenberghs G, Neyens T, Hens N, et al
    Empirical analysis of COVID-19 confirmed cases, hospitalizations, vaccination, and international travel across Belgian provinces in 2021.
    PLoS One. 2025;20:e0322017.
    PubMed         Abstract available

  31. KULJANCIC D, Amidzic J, Ljubotin L, Siladji D, et al
    Clinical profile of alcohol dependent paintents according to Lesch Typology one year after the Covid-19 pandemic-comparative study.
    PLoS One. 2025;20:e0324851.
    PubMed         Abstract available


  32. Retraction: Comprehensive computational analysis reveals H5N1 influenza virus-encoded miRNAs and host-specific targets associated with antiviral immune responses and protein binding.
    PLoS One. 2025;20:e0325170.
    PubMed        

  33. COLMAN E, Kao R
    The impact of signal variability on COVID-19 epidemic growth rate estimation from wastewater surveillance data.
    PLoS One. 2025;20:e0322057.
    PubMed         Abstract available

  34. WANG CN, Nguyen TTM, Nhieu NL, Chung YC, et al
    Performance evaluation of Vietnamese industrial goods and services during and post-COVID-19 era based on multi-criteria decision-making methods.
    PLoS One. 2025;20:e0323764.
    PubMed         Abstract available

  35. VAN DER MOEREN N, van den Biggelaar R, Gast KB, Verweij JJ, et al
    The added diagnostic value of RT-PCR on faeces for the diagnosis of COVID-19.
    PLoS One. 2025;20:e0322543.
    PubMed         Abstract available

  36. BENTAHAR I, Loubet P, Salipante F, Choquet C, et al
    Respiratory viruses Ct values and association with clinical outcomes among adults visiting the ED with lower respiratory tract infections.
    PLoS One. 2025;20:e0320503.
    PubMed         Abstract available


    Vaccine

  37. RAHIMI HK, Jasim AA, Rezahosseini O, Harboe ZB, et al
    Immunogenicity and adverse effects of pneumococcal vaccines co-administered with influenza or SARS-CoV-2 vaccines in adults: A systematic review and Meta-analysis.
    Vaccine. 2025;59:127293.
    PubMed         Abstract available

  38. QUENTIN E, Ahmed I, Duong CH, Tubert-Bitter P, et al
    Covid-19 Vaccination During Pregnancy in France: a Descriptive Study of Uptake Using the National Healthcare data System.
    Vaccine. 2025;58:127223.
    PubMed         Abstract available

  39. LUPTON D, Whitten T, Tay AK, Beek K, et al
    Mental health and psychosocial factors predicting concerns about the COVID-19 vaccine among refugee background and Australian-born women.
    Vaccine. 2025;58:127251.
    PubMed         Abstract available

  40. AVERIN A, Quinn E, Atwood M, Weycker D, et al
    Cost-effectiveness of bivalent respiratory syncytial virus Prefusion F (RSVpreF) maternal vaccine among infants in the United States.
    Vaccine. 2025;58:127191.
    PubMed         Abstract available

  41. SASAKI E, Hamaguchi I, Hasegawa H, Takahashi Y, et al
    Establishment of a novel adjuvant screening system for the development of intranasal vaccine adjuvants.
    Vaccine. 2025;58:127267.
    PubMed         Abstract available

  42. MOORE DCBC, Nehab MF, Reis AT, Junqueira-Marinho MF, et al
    Childhood vaccine hesitancy: The power of metaphors.
    Vaccine. 2025;58:127221.
    PubMed         Abstract available

  43. PATTYN J, Hanning N, Valckx S, Claessens T, et al
    Investigating the state of vaccine confidence among the general public and parents with children up to 13 years in Flanders (Belgium).
    Vaccine. 2025;58:127250.
    PubMed         Abstract available

  44. MERRITT A, Bansal S
    Prison Vaccination in a pandemic: Geographic disparities and policy insights.
    Vaccine. 2025;58:127218.
    PubMed         Abstract available

  45. PEARCE A, Henery P, Dundas R, Katikireddi SV, et al
    Socio-economic inequalities in uptake and timing of childhood vaccination: Taking a life course approach in an administrative cohort in Scotland.
    Vaccine. 2025;57:127222.
    PubMed         Abstract available

  46. WANG-LU H, Valerio Mendoza OM, Chen S, Geldsetzer P, et al
    Regional mobility and COVID-19 vaccine hesitancy: Evidence from China.
    Vaccine. 2025;58:127179.
    PubMed         Abstract available

  47. STEPANEK L, Nakladalova M, Borikova A, Horakova D, et al
    Measles-mumps-rubella booster and post-COVID-19 immunity: A retrospective cohort study.
    Vaccine. 2025;57:127232.
    PubMed         Abstract available

  48. ADAME BJ, Corman SR, Von Feldt PA, Meneses CM, et al
    Reactance as a cause of COVID-19 vaccination hesitancy.
    Vaccine. 2025;57:127209.
    PubMed         Abstract available

  49. ROULEAU I, Issa Kana KDN, Zafack JG, Viger YB, et al
    New-onset anesthesia/paresthesia following the administration of COVID-19 vaccines in Quebec, Canada.
    Vaccine. 2025;57:127217.
    PubMed         Abstract available

  50. MALANGE V, Mohaissen T, Conway KM, Rhoads A, et al
    Influenza vaccination during early pregnancy and risk of major birth defects, US Birth Defects Study To Evaluate Pregnancy exposureS, 2014-2019.
    Vaccine. 2025;59:127297.
    PubMed         Abstract available

  51. SEILER P, Kaplan BS, Brice DC, Duan S, et al
    Altered germinal center responses in mice vaccinated with highly pathogenic avian influenza A(H5N1) virus.
    Vaccine. 2025;60:127311.
    PubMed         Abstract available


    Virology

  52. LENDE SSF, Rothemejer FH, Andreas M, Pedersen ML, et al
    Vectored long-term co-delivery of antibodies for SARS-CoV-2, RSV and Influenza prophylaxis.
    Virology. 2025;610:110573.
    PubMed         Abstract available

Comments

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...